Asimov and AGC Biologics Collaborate to Advance Viral Vector Manufacturing

To use Asimov’s LV Edge Packaging Cell Line technology at AGC Biologics Cell and Gene Center of Excellence in Milan, Italy, the two companies have signed a strategic licensing agreement. By employing single-plasmid transfection techniques, the partnership seeks to streamline the production of lentiviral vectors, providing gene therapy scientists with increased productivity, enhanced scalability, and a more economical manufacturing process. By increasing process consistency and decreasing production complexity, the platform is intended to address major manufacturing difficulties. It is anticipated that this partnership will ensure high-quality vector production by assisting therapeutic developers in expediting the shift from clinical development to commercial manufacturing.

Strengthening Scalable Manufacturing for Gene Therapy

The LV Edge Packaging Cell Line platforms are intended to simplify the manufacture of lentiviral vectors by lowering manufacturing complexity and enhancing process uniformity. AGC Biologics hopes to expedite the manufacture of superior viral vectors needed for clinical and commercial gene therapy initiatives by incorporating this cutting-edge technology into its production processes. As additional cell and gene therapies get closer to commercialization, the partnership is anticipated to help meet the increasing need for scalable manufacturing solutions. By lowering the quantity of plasmids needed for production, it also improves manufacturing flexibility and operating efficiency. The collaboration is a reflection of the industry's growing emphasis on cutting-edge production systems that can support genetic medications of the future.

According to Precedence Research, the viral vectors and plasmid DNA manufacturing market size was valued at USD 7.26 billion in 2025 and is projected to grow from USD 8.42 billion in 2026 to approximately USD 29.82 billion by 2035, expanding at a CAGR of 15.17% during the forecast period from 2026 to 2035, driven by the increasing commercialization of gene and cell therapies, rising investments in biopharmaceutical manufacturing, and expanding demand for high-quality viral vector production.

Industry Impact and Market Outlook

The Asimov and AGC Biologics collaboration demonstrate the industry's increasing focus on creating scalable, effective, and affordable manufacturing platforms for cutting-edge treatments. Manufacturers are investing in cutting-edge production technologies that boost yields, shorten production times, and facilitate commercial-scale manufacturing as the need for viral vectors keeps rising. These developments facilitate wider access to cutting-edge treatments and assist in the removal of current industrial constraints. Global manufacturing skills are also being strengthened by growing partnerships between CDMOs and technology providers.